|
发表于 2012-2-7 17:32:36
|
显示全部楼层
来自: 中国广东湛江
REFERENCES
1. ↵
1. Buie LW,
2. Lindley C,
3. Shih T,
4. et al.
(2007) Plasma pharmacokinetics and cerebrospinal fluid concentrations of erlotinib in high-grade gliomas: A novel, phase I, dose escalation study. J Clin Oncol 25(suppl):88s, abstr 2054.
2. ↵
1. Grossman SA,
2. Krabak MJ
(1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25:103–119.
CrossRefMedline
3. ↵
1. Pentheroudakis G,
2. Pavlidis N
(2005) Management of leptomeningeal malignancy. Expert Opin Pharmacother 6:1115–1125.
CrossRefMedline
4. ↵
1. Sakai M,
2. Ishikawa S,
3. Ito H,
4. et al.
(2006) Carcinomatous meningitis from non–small-cell lung cancer responding to gefitinib. Int J Clin Oncol 11:243–245.
CrossRefMedline
5. ↵
1. Jackman DM,
2. Holmes AJ,
3. Lindeman N,
4. et al.
(2006) Response and resistance in a non–small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 24:4517–4520.
FREE Full Text
6.
1. Choong NW,
2. Dietrich S,
3. Seiwert TY,
4. et al.
(2006) Gefitinib response of erlotinib-refractory lung cancer involving meninges: Role of EGFR mutation. Nat Clin Pract Oncol 3:50–57.
CrossRefMedline
7.
1. Fukuhara T,
2. Saijo Y,
3. Sakakibara T,
4. et al.
(2008) Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene. Tohoku J Exp Med 214:359–363.
CrossRefMedline
8. ↵
1. Wagner M,
2. Besse B,
3. Balleyguier C,
4. et al.
(2008) Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma. J Thorac Oncol 3:677–679.
CrossRefMedline
|
|